← Back to Search

Insulin-Like Growth Factor 1 for Aging Skin

Q: How many participants have been recruited for this trial?

<p>Affirmative, the clinicaltrials.gov information indicates that this medical experiment is actively seeking enrolment at present. This endeavor was initially posted on September 6th 2019 and has been renewed most recently on March 11th 2022. 24 participants must be sourced from just one centre for it to reach completion.</p>

Q: Are there still vacancies in this research project for participants?

<p>Per information found on clinicaltrials.gov, this medical trial is currently open for enrollment and began accepting applications from the public back on September 6th 2019. It has since been updated as recently as March 11th 2022.</p>

Phase < 1

Recruiting

Led By Jeffrey B Travers, MD, PhD

Research Sponsored by Wright State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 21-30 or 65 and older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 days

Awards & highlights

Study Summary

This trial is testing whether artificial sunlight affects young adult skin differently than older skin, and if older skin will respond to a drug injection the same as young skin.

Who is the study for?

This trial is for healthy adults aged 21-30 or 65 and older with white skin (Fitzpatrick types I and II). Participants must understand the procedures and risks. Those with allergies to lidocaine, serious health issues, on photosensitizing meds, diabetes, abnormal scarring history, skin infections, pregnancy/nursing or known photosensitivity cannot join.Check my eligibility

What is being tested?

The study investigates how young adult versus geriatric skin responds to artificial sunlight (UVB). It will test if treating geriatric skin with an injection of IGF-1 makes it respond like young skin. The intervention includes exposure to UVB and possibly receiving an IGF-1 injection.See study design

What are the potential side effects?

Potential side effects may include reactions similar to sunburn from UVB exposure such as redness or pain. There might also be local reactions at the injection site if treated with IGF-1 like swelling or discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am either between 21-30 years old or 65 and older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in expression genes involved in protecting skin cells from UVB damage in younger skin and geriatric skin injected with IGF-1 from baseline

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Geriatric AdultActive Control1 Intervention

Four small areas will undergo injection of a small amount of IGF-1 drug and two will undergo injections with saline. Then the injected areas will be treated with a small amount of UVB.

Group II: Young AdultPlacebo Group1 Intervention

One small area of skin will undergo treatment with a small amount of UVB.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Wright State UniversityLead Sponsor

41 Previous Clinical Trials

54,858 Total Patients Enrolled

1 Trials studying Aging

72 Patients Enrolled for Aging

Jeffrey B. Travers, MD, PhDLead Sponsor

4 Previous Clinical Trials

132 Total Patients Enrolled

1 Trials studying Aging

72 Patients Enrolled for Aging

Jeffrey B Travers, MD, PhDPrincipal InvestigatorWright State University

9 Previous Clinical Trials

236 Total Patients Enrolled

1 Trials studying Aging

72 Patients Enrolled for Aging

Media Library

No Insulin-Like Growth Factor 1 Clinical Trial Eligibility Overview. Trial Name: NCT03932162 — Phase < 1

Aging Research Study Groups: Young Adult, Geriatric Adult

Aging Clinical Trial 2023: No Insulin-Like Growth Factor 1 Highlights & Side Effects. Trial Name: NCT03932162 — Phase < 1

No Insulin-Like Growth Factor 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT03932162 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have been recruited for this trial?

"Affirmative, the clinicaltrials.gov information indicates that this medical experiment is actively seeking enrolment at present. This endeavor was initially posted on September 6th 2019 and has been renewed most recently on March 11th 2022. 24 participants must be sourced from just one centre for it to reach completion."

Answered by AI

Are there still vacancies in this research project for participants?

"Per information found on clinicaltrials.gov, this medical trial is currently open for enrollment and began accepting applications from the public back on September 6th 2019. It has since been updated as recently as March 11th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Gene Expression Changes In Young and Geriatric Skin

Jeffrey B. Travers, MD, PhD 2019. "Gene Expression Changes In Young and Geriatric Skin". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03932162.

All > Insulin